



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Seneviratna, R;Redmond, SJ;McWilliam, HEG;Reantragoon, R;Villadangos, JA;McCluskey, J;I Godfrey, D;Gherardin, NA

Title:

Corrigendum to: Differential antigenic requirements by diverse MR1-restricted T cells (Immunology & Cell Biology, (2022), 100, 2, (112-126), 10.1111/imcb.12519)

Date:

2022-03-01

Citation:

Seneviratna, R., Redmond, S. J., McWilliam, H. E. G., Reantragoon, R., Villadangos, J. A., McCluskey, J., I Godfrey, D. & Gherardin, N. A. (2022). Corrigendum to: Differential antigenic requirements by diverse MR1-restricted T cells (Immunology & Cell Biology, (2022), 100, 2, (112-126), 10.1111/imcb.12519). Immunology and Cell Biology, 100 (3), pp.218-. <https://doi.org/10.1111/imcb.12535>.

Persistent Link:

<https://hdl.handle.net/11343/333405>

CORRIGENDUM

Differential antigen requirements by diverse MR1-restricted T cells

Rebecca Seneviratna^{1,2a}, Samuel J Redmond^{1,2a}, Hamish EG McWilliam^{1,3}, Rangsim Reantragoon¹, Jose A Villadangos^{1,3}, James McCluskey¹, Dale I Godfrey^{1,2} & Nicholas A Gherardin^{1,2}

¹Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC 3000, Australia

²Australian Research Council Centre of Excellence in Advanced Molecular Imaging, University of Melbourne, Parkville, VIC 3010, Australia

³Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC 3010, Australia

Correction to: *Immunol Cell Biol* 2022; **100**: 112–126. doi: 10.1111/imcb.12519.

[Typeset 2-column format for the text below, refer to layout of *IMCB* 12507]

The authors omitted a grant from the National Institutes of Health (NIH, #R01AI148407) in the Acknowledgments section. The corrected version appears below. The authors apologise for this error.

Acknowledgments

We thank staff from the flow cytometry facilities at the Department of Microbiology and Immunology at the Peter Doherty Institute. We thank Dr Lars Kjer-Nielsen for his role in the provision of C1R.MR1 mutants used in TCR ala-scan experiments, Associate Professor Andreas Behren (Olivia Newton-John Cancer Research Institute, Australia) for provision of human melanoma “LM-MEL” cell lines and Professor David Fairlie (University of Queensland, Australia) for the provision of 5-OP-RU and 5-amino-6-Dribitylaminouracil. This work was supported by the Australian Research Council (ARC; CE140100011 and DP170102471), the National Health and Medical Research Council of Australia (NHMRC; 1113293, 1159932 and 2003192) and the National Institutes of Health (NIH, R01AI148407). NAG and HEGM were supported by ARC DECRA Fellowships (DE210100705 and DE170100575). DIG was supported by an NHMRC Senior Principal Research Fellowship (1117766). JAV was supported by an NHMRC Principal Research Fellowship (1154502). Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/imcb.12535](https://doi.org/10.1111/imcb.12535)

This article is protected by copyright. All rights reserved